Accenture invierte en Sam Altman y Y Combinator, la startup de biotecnología respaldada por 1910 Genetics
Accenture ha invertido en 1910 Genetics, una startup de biotecnología respaldada por el director ejecutivo de OpenAI, Sam Altman, y Y Combinator. Esta inversión tiene como objetivo revolucionar el descubrimiento de fármacos utilizando soluciones impulsadas por Al.
Los términos de la inversión no fueron revelados.
Para el descubrimiento de fármacos impulsado por Al, 1910 Genetics utiliza su plataforma patentada de Al multimodal llamada Entrada-Transformación-Salida (ITOTM) para mejorar el descubrimiento de fármacos para terapias con moléculas grandes y pequeñas. Esta plataforma integra cientos de modelos de Al y emplea aprendizaje federado para optimizar el diseño de moléculas y la identificación de objetivos.
La colaboración Accenture-1910 tiene como objetivo proporcionar a los clientes de biofarmacia una poderosa plataforma de Al que simplifique el proceso de descubrimiento de fármacos, reduzca los costos y mejore los resultados de los pacientes.
La startup de biotecnología, 1910 Genetics, que se lanzará en 2021, está respaldada por importantes inversores, incluidos M12: Microsoft’s Venture Fund, Playground Global, Sam Altman, Y Combinator, FoundersX Ventures y Scientia Ventures.
The goal of the investment by Accenture is to collaborate with 1910 Genetics wherein Accenture brings its AI and enterprise scalability expertise to the table, while the biotech startup contributes its comprehensive AI platform. Together, they aim to drive innovation in drug discovery and therapeutic development.
Key figures from both companies will join advisory boards, and 1910 Genetics will join Accenture Ventures’ Project Spotlight for emerging technologies. Dr. Petra Jantzer and Tom Lounibos will join the Business Advisory Board of 1910, and Dr. Kailash Swarna, a managing director in Life Sciences at Accenture, and Dr. Cecil Lynch, Biomedical Informatics lead at Accenture, will join the Technology Advisory Board of 1910.
This partnership is expected to significantly impact the biopharma industry by enhancing efficiency and accelerating the development of new therapies.
The global drug discovery market is projected to reach USD 76.5 billion by 2033, growing at a compound annual growth rate (CAGR) of 14.5% from 2023 to 2033. North America currently dominates the market, but Asia-Pacific is expected to see significant growth due to increasing investments in R&D and the expansion of the pharmaceutical industry.
It may be recalled that, in middle of this year, a CNBC report said that the AI-powered healthcare field is on a path that will see medicines completely generated by Artificial Intelligence (AI) in the near future.
In addition to 1910 Genetics, Accenture has made several other strategic investments and collaborations in the drug discovery space. In August, Accenture announced it has invested in Ocean Genomics to accelerate Al-driven drug discovery and the development of personalized medicines. Ocean Genomics uses advanced computational platforms to assist biopharma companies in discovering and developing more effective diagnostics and Therapeutics.
Accenture has partnered with Exscientia, a leading AI-driven drug discovery company, to leverage its AI platform for accelerating the discovery of new therapeutic compounds. Further, Accenture also collaborated with Schrödinger to enhance its computational platform for drug discovery. Schrödinger’s platform integrates physics-based computational software to design novel molecules with improved accuracy.
Related Posts
Magnífico Meta y Microsoft
¿Quién es Kemi Badenoch, líder de la oposición británica nacida en Nigeria y la primera mujer negra en conseguir un trabajo?
